4Filed Aug 26, 8:00 PM ET

Forte Biosciences (FBRX) Director Vincent Richard G Cancels 51,353 Awards

$FBRX · Forte Biosciences, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Forte Biosciences (FBRX) Director Vincent Richard G Cancels 51,353 Awards

What Happened
Vincent Richard G, a director of Forte Biosciences, reported dispositions to the issuer on August 27, 2026, totaling 51,353 derivative units (2,000 + 31,000 + 18,353). These were not open-market sales but cancellations/conversions of company options and restricted stock units (RSUs) in connection with the Merger Agreement described in the filing. The Form 4 reports the transactions as derivative dispositions and shows the price/total value as N/A.

Key Details

  • Transaction date: 2026-08-27 (Filed same day; no late filing noted).
  • Reported dispositions: 2,000; 31,000; and 18,353 derivative units (total 51,353).
  • Transaction type: Disposition to issuer (derivative awards canceled/converted under merger).
  • Price / total cash received: Not reported on the Form 4 (listed as N/A).
  • Shares owned after transaction: Not stated in the filing.
  • Relevant footnotes (summarized):
    • Options with exercise price below the Merger Consideration were canceled and converted into a lump-sum cash payment equal to the excess of the Merger Consideration over the exercise price multiplied by the option shares (F1).
    • Options with exercise price equal to or above the Merger Consideration were canceled for no consideration (F2).
    • Each RSU represented a right to one share and was canceled for a cash payment equal to the Merger Consideration times the RSU shares (F3–F4).
    • Payments are subject to applicable withholding taxes per the footnotes.

Context
These dispositions reflect corporate-level treatment of equity awards in connection with the merger (conversion/cancellation for cash), not a voluntary open-market sale by the director. Because the Form 4 does not state the Merger Consideration amount or the cash paid for these specific awards, investors should not infer the dollar proceeds from this filing alone. Dispositions of derivative awards in mergers are routine and typically governed by agreement terms rather than being direct signals of insider sentiment.